alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**Exhibit 99.1**

 

**ANNUAL SERVICER’S CERTIFICATE**

 

**TARGET NATIONAL BANK**

 

**TARGET CREDIT CARD MASTER TRUST**

 

The undersigned, a dulyauthorized representative of Target National Bank, as Servicer,  pursuantto the Amended and Restated Pooling and Servicing Agreement dated as of April28, 2000,  as supplemented by the Series 2002-1 Supplement, dated as of July 2,2002 and the Series 2005-1  Supplement, dated as of November 9, 2005 (asamended and supplemented from time to time, the  “Agreement”),among Target Receivables Corporation, as Transferor, Target National Bank, as  Servicer,and Wells Fargo Bank, National Association, as Trustee, does hereby certifythat:

 

1.             Target National Bank is, as of thedate hereof, the Servicer under the Agreement.  Capitalizedterms used in this Certificate have their respective meanings as set forth inthe Agreement.

 

2.             The undersigned is a ServicingOfficer who is duly authorized pursuant to the  Agreementto execute and deliver this certificate to the Trustee.

 

3.             A review of the activities of theServicer during the fiscal year ended December 31, 2005,  andof its performance under the Agreement was conducted under my supervision.

 

4.             Based on such review, the Servicerhas, to the best of my knowledge, performed in all  materialrespects its obligations under the Agreement throughout such year and nodefault in the  performance of such obligations has occurredor is continuing except as set forth in paragraph 5 below.

 

5.             The following is a description ofeach default in the performance of the Servicer’s  obligationsunder the provisions of the Agreement known to me to have been made by theServicer  during the fiscal year ended December 31,2005 which sets forth in detail (i) the nature of each default,  (ii)the action taken by the Servicer, if any, to remedy each such default and (iii)the current status of  each such default: None.

 

IN WITNESS WHEREOF, theundersigned has duly executed this Certificate as of the  31stday of March, 2006.

 
| ** ** | ** ** | **TARGET NATIONAL BANK,**            |   |
|------------|------------|--------------------------------------|--------|
| ** ** | ** ** | **as Servicer,**                     |   |
| ** ** | ** ** |                                 |   |
| ** ** | ** ** |                                 |   |
| ** ** | **By:**    | /s/  Thomas A. Swanson               |   |
|       |       | Name:  Thomas A. Swanson             |
|       |       | Title:  Vice President & Cashier |
|            |            |                                      |        |  |

 

----
§ 516.26 Amendment to MUMS-drug designation. ( a ) At any time prior to conditional approval or approval of an application for a MUMS-designated drug, the sponsor may apply for an amendment to the designated intended use if the proposed change is due to new and unexpected findings in research on the drug, information arising from FDA recommendations, or other unforeseen developments.
( b ) FDA will grant the amendment if it finds: ( 1 ) That the initial designation request was made in good faith;
( 2 ) That the amendment is intended to make the MUMS-drug designated intended use conform to the results of new and unexpected findings in research on the drug, information arising from FDA recommendations, or other unforeseen developments; and
( 3 ) In the case of a minor use, that as of the date of the submission of the amendment request, the amendment would not result in the intended use of the drug no longer being considered a minor use.
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1875 Thiamine hydrochloride. ( a ) Thiamine hydrochloride (C12H17C1N4OS·HCl, CAS Reg. No. 67-03-8) is the chloride-hydrochloride salt of thiamine. It occurs as hygroscopic white crystals or a white crystalline powder. The usual method of preparing this substance is by linking the preformed thiazole and pyrimidine ring systems.
( b ) The ingredient meets the specifications of the Food Chemicals Codex, 3d Ed. (1981), p. 324, which is incorporated by reference. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as a flavoring agent and adjuvant as defined in § 170.3(o)(12) of this chapter or as a nutrient supplement as defined in § 170.3(o)(20) of this chapter.
( 2 ) The ingredient is used in food at levels not to exceed current good manufacturing practice. Thiamine hydrochloride may be used in infant formula in accordance with section 412(g) of the Federal Food, Drug, and Cosmetic Act (the Act) or with regulations promulgated under section 412(a)(2) of the Act.
( d ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[48 FR 55124, Dec. 9, 1983]
§ 522.1704 Pentosan polysulfate sodium. ( a ) *Specifications.* Each milliliter of solution contains 250 milligrams (mg) of pentosan polysulfate sodium.
( b ) *Sponsor.* See No. 043264 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount.* Administer 3 mg per kilogram of body weight (1.4 mg per pound) by intramuscular injection once weekly for 4 weeks for a total of four doses.
( 2 ) *Indications for use.* For the control of clinical signs associated with osteoarthritis in horses.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[88 FR 16548, Mar. 20, 2023, as amended at 88 FR 84701, Dec. 6, 2023]
Federal Aviation Administration Attention: Hearing Docket Clerk, AGC-430 WilburWright Building-Suite 2Wl000 800 Independence Avenue, SW Washington, DC 20591 May30, 2016
RE: Case Name:

Dear Administrator: Endless Mountains Air, Inc. DocketNo. FAA-2013-0848 Case No. 2012EA050008 

### SeamansAirport 65 WindsockLane Factoryville, PA 18419

Phone: 570.945.5125 e-mail: billy@seamansairport.com website: www.seamansairport.com 

# RECEIVED
JUN 072016 

## HEARING DOCKET

Pleasebe advised that Endless Mountains Air, Inc. disagrees withthe Initial Decision ofU.S. Administrative Law Judge J.E. Sullivan and requests the opportunity to appeal the decision and subsequent civil penalty of $16,200.
Atthe time ofour hearing, current taxreturns had not been filed byEndless Mountains Air, Inc and therefore could not be submitted to Judge Sullivan for review in our case. The reason for our delinquency with filing returns was due to the corporationhaving a large overdue balance with our accountants ofwhich we were unable to satisfyprior to our March 10,2015 hearing. We were therefore unable to payfor tax return preparation since 2012 and were unfortunately unable to enter current returns as evidence at our hearing. Thankfully, we have satisfied our outstanding balance with our accountant and are only nowbegiuning to work toward completion ofour overdue returns.
I strongly believe that with review ofrecent federal tax returns, the Administrator will find that Endless Mountains Air is clearly unable to pay such a large civil penalty.
Thank you for your consideration. Ifyou have any questions, please feel free to contact me at any time. Sincerely, 

### -)

. Dobitsch, Jr., President ountains Air, Inc.SERVICE LIST- BY

### U.S. MAIL
ORIGINAL & ONE COPY


### Federal Aviation Administration 800 Independence Avenue, S.W. Washington, DC 20591 Attention: Hearing Docket Clerk, AGC-430 Wilbur Wright Building- Suite 2Wl0001

Mr. 

### Zachary M. Berman Complainant's Counsel Office ofRegional Counsel, Eastern Region Federal Aviation Administration 1 Aviation Plaza Jamaica, NY 11434 TEL: 718-553-3258 FAX: 718-995-5699

Mr. WilliamJ. Dobitsch, Jr. Endless Mountains Air, Inc. Respondent Seamans Airport 65 Windsock Lane Factoryville, PA 18419 TEL: 570-945-5125 FAX: 570-945-5953

Judge J.E. Sullivan U.S. Administrative Law Judge Office ofHearings, M-20 U.S. Department ofTransportation 1200 NewJersey Avenue, S.E. (E11-310) Washington, DC 20590 TEL: 202-366-6941 FAX: 202-366-7536 ONE COPY
UNITED STATES DISTRICT COURT

FOR THE DISTRICT OF COLUMBIA

Crim. Action No. 05-00272 (CKK) 

ORDER

May 10, 2022

This case comes before the Court upon the receipt of a Report and Recommendation 

dated April 25, 2022, from Magistrate Judge G. Michael Harvey. See ECF No. 59. No 

objections to the Magistrate Judge’s Report and Recommendation have been received by the 

Court.

Accordingly, it is this 10th day of May, 2022, 

ORDERED that the Report and Recommendation is hereby ADOPTED. Defendant 

Reginald Russell’s supervised release, which expired on March 23, 2022, shall be deemed 

terminated as unsuccessful, and Defendant shall not be reincarcerated for his recent failed drug 

tests.

_________/s/_____________________

COLLEEN KOLLAR-KOTELLY

UNITED STATES DISTRICT JUDGE

UNITED STATES OF AMERICA,

 v.

REGINALD RUSSELL,

 Defendant.
§ 524.1146 Imidacloprid and moxidectin. ( a ) *Specifications.* Each milliliter of solution contains: ( 1 ) 100 milligrams (mg) imidacloprid and 25 mg moxidectin; or
( 2 ) 100 mg imidacloprid and 10 mg moxidectin.
( b ) *Sponsors.* See sponsor numbers in § 510.600(c) of this chapter as follows: ( 1 ) Nos. 017030, 051072, 051311, 055529, and 058198 for use of product described in paragraph (a)(1) of this section as in paragraph (d)(1) of this section.
( 2 ) Nos. 017030, 051072, 051311, 055529, and 058198 for use of product described in paragraph (a)(2) of this section as in paragraph (d)(2) of this section.
( 3 ) Nos. 051072, 055529, 058198, and 061651 for use of product described in paragraph (a)(2) of this section as in paragraph (d)(3) of this section.
( c ) *Special considerations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( d ) *Conditions of use* — ( 1 ) *Dogs* — ( i ) *Amount.* Topically apply 4.5 mg/lb body weight (10 mg/kg) imidacloprid and 1.1 mg/lb (2.5 mg/kg) moxidectin, once a month.
( ii ) *Indications for use.* ( A ) For the prevention of heartworm disease caused by *Dirofilaria immitis*; and the treatment and control of intestinal roundworms (*Toxocara canis* and *Toxascaris leonina*), hookworms (*Ancylostoma caninum* and *Uncinaria stenocephala*), and whipworms (*Trichuris vulpis*); kills adult fleas and treats flea infestations (*Ctenocephalides felis*).
( B ) For treatment of *Dirofilaria immitis* circulating microfilariae in heartworm-positive dogs and the treatment and control of sarcoptic mange caused by *Sarcoptes scabiei* var. *canis.*
( 2 ) *Cats* — ( i ) *Amount.* Topically apply 4.5 mg/lb body weight (10 mg/kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin, once a month.
( ii ) *Indications for use.* For the prevention of heartworm disease caused by *Dirofilaria immitis*; for the treatment and control of ear mite (*Otodectes cynotis*) infestations, intestinal roundworms (*Toxocara cati*), and hookworms (*Ancylostoma tubaeforme*); kills adult fleas and treats flea infestations (*Ctenocephalides felis*).
( 3 ) *Ferrets* — ( i ) *Amount.* Topically apply 9.0 mg/lb body weight (20 mg/kg) imidacloprid and 0.9 mg/lb (2 mg/kg) moxidectin, once a month.
( ii ) *Indications for use.* For the prevention of heartworm disease caused by *Dirofilaria immitis*; kills adult fleas (*Ctenocephalides felis*) and is indicated for the treatment of flea infestations on ferrets.
[72 FR 10597, Mar. 9, 2007, as amended at 78 FR 73698, Dec. 9, 2013; 85 FR 18120, Apr. 1, 2020; 86 FR 13185, Mar. 8, 2021; 86 FR 14821, Mar. 19, 2021; 87 FR 17946, Mar. 29, 2022; 87 FR 58963, Sept. 29, 2022; 88 FR 27700, May 3, 2023; 89 FR 14410, Feb. 27, 2024]
Editorial Note on Part 161
Editorial Note: Nomenclature changes to part 161 appear at 81 FR 49896, July 29, 2016.

§ 161.130 Oysters. ( a ) Oysters, raw oysters, shucked oysters, are the class of foods each of which is obtained by shucking shell oysters and preparing them in accordance with the procedure prescribed in paragraph (b) of this section. The name of each such food is the name specified in the applicable definition and standard of identity prescribed in §§ 161.131 to 161.140, inclusive.
( b ) If water, or salt water containing less than 0.75 percent salt, is used in any vessel into which the oysters are shucked the combined volume of oysters and liquid when such oysters are emptied from such vessel is not less than four times the volume of such water or salt water. Any liquid accumulated with the oysters is removed. The oysters are washed, by blowing or otherwise, in water or salt water, or both. The total time that the oysters are in contact with water or salt water after leaving the shucker, including the time of washing, rinsing, and any other contact with water or salt water is not more than 30 minutes. In computing the time of contact with water or salt water, the length of time that oysters are in contact with water or salt water that is agitated by blowing or otherwise, shall be calculated at twice its actual length. Any period of time that oysters are in contact with salt water containing not less than 0.75 percent salt before contact with oysters, shall not be included in computing the time that the oysters are in contact with water or salt water. Before packing into the containers for shipment or other delivery for consumption the oysters are thoroughly drained and are packed without any added substance.
( c ) For the purposes of this section: ( 1 ) *Shell oysters* means live oysters of any of the species, *Ostrea virginica, Ostrea gigas, Ostrea lurida,* in the shell, which, after removal from their beds, have not been floated or otherwise held under conditions which result in the addition of water.
( 2 ) *Thoroughly drained* means one of the following: ( i ) The oysters are drained on a strainer or skimmer which has an area of not less than 300 square inches per gallon of oysters, drained, and has perforations of at least 1 ⁄ 4 of an inch in diameter and not more than 11 ⁄ 4 inches apart, or perforations of equivalent areas and distribution. The oysters are distributed evenly over the draining surface of the skimmer and drained for not less than 5 minutes; or
( ii ) The oysters are drained by any method other than that prescribed by paragraph (c)(2)(i) of this section whereby liquid from the oysters is removed so that when the oysters are tested within 15 minutes after packing by draining a representative gallon of oysters on a skimmer of the dimensions and in the manner described in paragraph (c)(2)(i) of this section for 2 minutes, not more than 5 percent of liquid by weight is removed by such draining.
565 P.2d 1285

#### STATE of Arizona, Appellee, v. Marcelino Bologna VINDIOLA, Appellant.

No. 3648.

Supreme Court of Arizona, In Banc.

June 8, 1977.

Bruce E. Babbitt, Atty. Gen., William J. Schafer, III, Chief Counsel, Crim. Div., Galen H. Wilkes, Asst. Attys. Gen., Phoenix, for appellee.

Ross P. Lee, Maricopa County Public Defender, H. Allen Gerhardt, Jr., Deputy Public Defender, Phoenix, for appellant.

GORDON, Justice:

Appellant, Marcelino Bologna Vindiola, was originally convicted of burglary, first degree and on June 20, 1975, was placed on probation for a period of three years with one condition of probation being that he serve six months in the Maricopa County Jail. On July 2, 1975 appellant pled guilty to escape in violation of A.R.S. § 13-393 and on July 16 was placed on probation for a period of three years under the same terms and conditions of probation established in the prior probation.

Subsequently a petition to revoke appellant’s probations was filed. At the hearing on March 2, 1976 appellant admitted being in violation of the terms of his probation. Probation in both cases was revoked on March 15,1976 and appellant was sentenced to not less than two nor more than four years in the Arizona State Prison for each violation, to date from December 1,1975 for the escape probation. Appellant appeals from the revocation of the escape probation and sentence. (The other probation revocation was appealed separately.)

The facts necessary for this review are as follows: On June 20, 1975 when appellant was placed on probation for the burglary conviction, he received a copy of the terms and conditions of his probation. On July 16, 1975 when appellant was placed on probation for the escape conviction, the trial court imposed the same conditions as were established for the burglary conviction. The court asked appellant if he had a copy of those conditions and appellant answered that he did.

Appellant raises one issue on appeal. He argues his probation was improperly revoked because he was not given written notice of the terms and conditions of his probation as required by rule 27.7(c)1 Rules of Criminal Procedure, 17 A.R.S., which provides in part:

> *425“Probation shall not be revoked for violation of a condition or regulation of which the probationer has not received a written copy.”

We find no violation of Rule 27.7(c). Appellant told the trial court he had in his possession a copy of the probation conditions applicable to the escape conviction and on appeal he asserts nothing to the contrary. Appellant’s probation was revoked for violation of a condition of which he received a written copy. His admission of the violation shows he was aware of the condition. Both the letter and the spirit of the pertinent provision of Rule 27.7(c) were met.

For the foregoing reasons, the probation revocation and sentence are affirmed.

CAMERON, C. J., STRUCKMEYER, V. C. J., and HAYS and HOLOHAN, JJ., concur.

1

. Actually, appellant argued on the basis of Rule 27.7(d) but the rule was amended effective August 1, 1975 and the pertinent provision is now incorporated in part (c).
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### National Science Foundation

In accordance with the Federal Advisory Committee Act (Public Law 92-463, as amended), the National Science Foundation announces the following meeting:

*Name:*                     Advisory Committee for Environmental Research and Education (9487).                

*Dates:*                     March 18, 2010, 8:30 a.m.-5 p.m.  March 19, 2010, 8:30 a.m.-1 p.m.                

*Place:*                     Stafford I, Room 375, National Science Foundation, 4201 Wilson Blvd., Arlington, Virginia 22230.                

*Type of Meeting:*                     Open.                

*Contact Person:*                     Melissa Lane, National Science Foundation, Suite 705, 4201 Wilson Blvd., Arlington, Virginia 22230. Phone 703-292-8500.                

*Minutes:*                     May be obtained from the contact person listed above.                

*Purpose of Meeting:*                     To provide advice, recommendations, and oversight concerning support for environmental research and education.                

## Agenda

### March 18, 2010

    - Update on recent NSF environmental activities.
    - Discussion of Approaches to Managing Interdisciplinary Research at NSF.
    - Meeting with the Director.

###  March 19, 2010

    - Discussion on Expanding NSF Research Portfolio for Science, Engineering and Education for Sustainability (SEES).
    - Discussion of NSF FY 2010 Climate Research Solicitations.

Dated: February 23, 2010.

Susanne Bolton,

Committee Management Officer.

[FR Doc. 2010-3972 Filed 2-25-10; 8:45 am]

BILLING CODE 7555-01-P
<PAGE>
                                                                    Exhibit 10.1

                       CONSENT OF INDEPENDENT ACCOUNTANTS

We hereby consent to the incorporation by reference in the Registration
Statements (Forms F-3 No. 333-12096, No. 333-13550 and No. 333-84510) of
Deutsche Telekom AG and in the related Prospectuses of our report dated March
17, 2003, with respect to the consolidated financial statements of Deutsche
Telekom AG included in this Annual Report on Form 20-F/A for the year ended
December 31, 2002.

June 26, 2003



Ernst & Young
Deutsche Allgemeine Treuhand AG
Wirtschaftspruefungsgesellschaft
Stuttgart



(Prof. Dr. Pfitzer)                         (Hollweg)
Wirtschaftspruefer                          Wirtschaftspruefer


PwC Deutsche Revision
Aktiengesellschaft
Wirtschaftspruefungsgesellschaft
Frankfurt am Main



(Frings)                                    (Laue)
Wirtschaftspruefer                          Wirtschaftspruefer